ArticleHead and neck pathology2026
Pathology-informed Generative Adversarial Network Augmentation Improves Classification of Peripheral Nerve Sheath Tumors by Modeling Morphological Variability: A Pilot Investigation.
Article in Head and neck pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeripheral nerve sheath tumors (PNSTs) of the head and neck (H&N) show histopathological overlap. Although convolutional neural networks (CNNs) have demonstrated feasibility in soft tissue tumor classification, limited intra-class variability related to perineurioma remains a critical constraint for rare tumor subtypes.
methodsThis retrospective diagnostic accuracy study with internal validation included 30 patients diagnosed with PNSTs. Whole-slide images were digitized at 20× magnification and partitioned using a strict patient-wise split. Synthetic perineurioma patches were generated using a modified Pix2Pix-based Generative Adversarial Network (GAN) incorporating a bottleneck architecture and self-attention modules. Two morphology-driven augmentation strategies were evaluated: (1) intra-phenotypic expansion by cross-patient patch pairing within the sclerosing subtype and (2) inter-phenotypic interpolation by cross-phenotype patch pairing between sclerosing and intraneural variants. EfficientNetV2-B0 pre-trained on ImageNet was trained under three configurations: original dataset only, original + Experiment A synthetic patches, and original + Experiment B synthetic patches. All performance metrics were computed exclusively on an independent yet internal test set composed of original images.
resultsGAN-based augmentation improved global classification performance compared with the baseline model trained on original images only (accuracy 0.733). Intra-phenotypic expansion increased accuracy to 0.767 and achieved the highest balanced accuracy (0.750) and macro-F1 (0.740). Inter-phenotypic interpolation yielded the highest overall accuracy and competitive multiclass agreement metrics. Perineurioma recall improved from 0.34 (baseline) to 0.51 with intra-phenotypic augmentation and 0.47 with inter-phenotypic interpolation, while specificity remained ≥ 0.999 across all strategies.
conclusionsStructured, pathology-informed GAN augmentation improved CNN classification of PNSTs, particularly for the morphologically heterogeneous perineurioma class. Intra-phenotypic expansion primarily improved rare-class sensitivity, whereas inter-phenotypic interpolation improved multiclass agreement and global robustness. These findings support morphology-driven synthetic enrichment as a clinically meaningful strategy to improve AI performance in underrepresented tumor entities and potentially support diagnostic decision-making in digital pathology environments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.